The effect of chronic digitalization on pump function in systolic heart failure.

BACKGROUND: Short- and intermediate-term use of cardiac glycosides promotes inotropy and improves the ejection fraction in systolic heart failure. AIM: To determine whether chronic digitalization alters left ventricular function and performance. METHODS: Eighty patients with mild-to-moderate systolic heart failure (baseline ejection fraction < or =45%) participated from our institution in a multi-center, chronic, randomized, double-blind study of digitalis vs. placebo. Of the 40 survivors, 38 (20 allocated to the digitalis arm and 18 to the placebo arm) were evaluated at the end of follow-up (mean, 48.4 months). Left ventricular systolic function was assessed by both nuclear ventriculography and echocardiography. The ejection fraction was measured scintigraphically, while the ventricular volumes were computed echocardiographically. RESULTS: The groups did not differ, at baseline or end-of-study, with respect to the ejection fraction and the loading conditions (arterial pressure, ventricular volumes and heart rate) by either intention-to-treat or actual-treatment-received analysis. Over the course of the trial, the digitalis arm exhibited no significant increase in the use of diuretics (18%, P=0.33), in distinction from the placebo group (78%, P=0.004), and a longer stay on study drug among those patients who withdrew from double-blind treatment (28.6 vs. 11.4 months, P=0.01). CONCLUSION: Following chronic use of digitalis for mild-to-moderate heart failure, cross-sectional comparison with a control group from the same inception cohort showed no appreciable difference in systolic function or performance. Thus, the suggested clinical benefit cannot be explained by an inotropic effect.

Circadian differences among 4,096 emergency department patients with acute asthma.

INTRODUCTION: In patients with asthma, airways narrow during the night. The clinical implications of a nocturnal presentation of patients with acute asthma to the emergency department (ED) are uncertain. OBJECTIVE: Our objective was to determine whether patients with asthma who had ED visits during the night (midnight to 7:59 am) vs. other times were more severe, responded less well to ED therapy, and had worse clinical outcomes. DESIGN AND SETTING: We performed a cohort study, as part of the Multicenter Airway Research Collaboration (n = 77 sites). ED patients with acute asthma, ages 2-54 yrs, underwent a structured interview in the ED. Chart review of missed/refusal patients created a truly consecutive case series. MEASUREMENTS AND MAIN RESULTS: Among 1,602 children, 19% presented at night Nighttime patients were more likely to be younger, male, and have a shorter duration of symptoms; there were no other clinical differences noted. Among 2,494 adults, 20% presented at night, and they were more likely to be female and to have a history of steroid use for asthma. Nighttime adults also had a shorter duration of symptoms and slightly lower peak flows (mean, 45% vs. 49% of predicted; p = .006) and were more likely to receive steroids. They were more likely to be intubated (2.0% vs. 0.2%; p < .001), but, overall, they were equally likely to be admitted or relapse after ED discharge. In contrast to objective measures of acute asthma severity, both nighttime children and adults were significantly less likely to report their asthma symptoms as severe. CONCLUSION: Except for endotracheal intubation (in adults only), circadian differences minimally affect ED presentation, therapy, or the outcomes of acute asthma. Nighttime asthmatics may be relatively insensitive to the symptoms of severe asthma.

Randomized trial of inhaled flunisolide versus placebo among asthmatic patients discharged from the emergency department.

STUDY OBJECTIVE: Inhaled corticosteroids (ICs) improve airflow and decrease symptoms in patients with chronic asthma. We examined whether high-dose inhaled flunisolide would have similar benefits after an emergency department visit for acute asthma. METHODS: Over a 16-month period at one inner-city ED, we documented 551 eligible patients (acute asthma; age 18 to 50 years; no ICs in past week; no oral corticosteroids in past month; and peak expiratory flow rate [PEFR] <70% of predicted value after first beta-agonist treatment); 104 patients agreed to participate. At ED discharge, all patients were given prednisone 40 mg/d for 5 days and inhaled beta-agonists as needed and were randomly assigned to receive high-dose inhaled flunisolide 2 mg/d (n=51) or placebo (n=53). Patients were telephoned daily and asked to return for PEFR measurement at 3, 7, 12, 21, and 24 days. RESULTS: Despite precautions, 28% (16 receiving flunisolide and 13 receiving placebo) of patients were completely lost to follow-up, 2 patients had only one follow-up (day 3), 2 patients receiving flunisolide withdrew because of medication-related bronchospasm, and 4 patients in each group experienced relapse. Among the 63 remaining patients, we found no difference between flunisolide and placebo at day 24 follow-up in percent predicted PEFR (87% versus 83% on day 24, P =.36; difference 4%, 95% confidence interval [CI] -5% to 13%). Nocturnal wheezing and nocturnal albuterol inhaler use was higher among patients receiving flunisolide than those receiving placebo on day 24 (48% versus 18% for nocturnal wheezing, P =.01; mean difference 30%, 95% CI 11% to 49%; 3.8 versus 1.4 nocturnal albuterol puffs, P =.03; mean difference 2.4 puffs, (95% CI 0.2 to 4). Levels of dyspnea, cough, and overall well-being were similar between the flunisolide and placebo groups. CONCLUSION: Addition of high-dose inhaled flunisolide to standard therapy does not benefit inner-city patients with acute asthma in the first 24 days after ED discharge. Airway inflammation during acute asthma may require higher doses or more potent anti-inflammatory agents.